We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Read MoreHide Full Article
Key Takeaways
Kymera Therapeutics gains $45M after Gilead exercises license option for KT-200 CDK2 degrader.
KYMR-Gilead deal offers up to $750M in milestones plus tiered royalties on future product sales.
Gilead plans IND-enabling studies for KT-200, targeting a 2027 regulatory filing timeline.
Kymera Therapeutics (KYMR - Free Report) announced that Gilead Sciences (GILD - Free Report) has exercised its option to obtain an exclusive license for Kymera’s KT-200, a first-in-class, oral cyclin-dependent kinase 2 (CDK2) molecular glue degrader (MGD) under their strategic collaboration agreement.
Concurrently, Kymera is entitled to a $45 million milestone payment.
Year to date, the shares of KYMR have rallied 12.3% compared with the industry’s 2.1% growth.
Image Source: Zacks Investment Research
KYMR-GILD Agreement for Molecular Glue CDK2 Degraders
In June 2025, Kymera entered into an exclusive option and license agreement with Gilead to accelerate the development and commercialization of a novel MGD program targeting CDK2 with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the agreement, Kymera is eligible to receive up to $750 million in total payments contingent on the achievement of specified development, regulatory and commercial milestones. The company has already realized $85 million in upfront and option exercise payments. Kymera stands to benefit from tiered royalties on net product sales, ranging from the high single digits to the mid-teens.
While Kymera leads all research activities for the CDK2 program, Gilead retains global rights to develop, manufacture and commercialize any products arising from the collaboration.
CDK2-directed MGDs are an emerging class of therapies that selectively eliminate the CDK2 protein — a key driver of tumor growth — rather than merely inhibiting its activity. This targeted approach has the potential to deliver safer and more effective oral treatments for CDK2-driven cancers, potentially improving outcomes, particularly in advanced breast cancer, where treatment options remain limited.
KT-200 demonstrated low-nanomolar CDK2 degradation, strong activity in CCNE1-driven models, potential brain penetration and a favorable safety profile in preclinical studies. It would be Kymera’s first molecular glue candidate to advance into clinical development.
Gilead plans to advance KT-200 into investigational new drug (IND)-enabling studies, with the goal of supporting an IND filing in 2027.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 9.68% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 9.95% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Key Takeaways
Kymera Therapeutics (KYMR - Free Report) announced that Gilead Sciences (GILD - Free Report) has exercised its option to obtain an exclusive license for Kymera’s KT-200, a first-in-class, oral cyclin-dependent kinase 2 (CDK2) molecular glue degrader (MGD) under their strategic collaboration agreement.
Concurrently, Kymera is entitled to a $45 million milestone payment.
Year to date, the shares of KYMR have rallied 12.3% compared with the industry’s 2.1% growth.
Image Source: Zacks Investment Research
KYMR-GILD Agreement for Molecular Glue CDK2 Degraders
In June 2025, Kymera entered into an exclusive option and license agreement with Gilead to accelerate the development and commercialization of a novel MGD program targeting CDK2 with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the agreement, Kymera is eligible to receive up to $750 million in total payments contingent on the achievement of specified development, regulatory and commercial milestones. The company has already realized $85 million in upfront and option exercise payments. Kymera stands to benefit from tiered royalties on net product sales, ranging from the high single digits to the mid-teens.
While Kymera leads all research activities for the CDK2 program, Gilead retains global rights to develop, manufacture and commercialize any products arising from the collaboration.
CDK2-directed MGDs are an emerging class of therapies that selectively eliminate the CDK2 protein — a key driver of tumor growth — rather than merely inhibiting its activity. This targeted approach has the potential to deliver safer and more effective oral treatments for CDK2-driven cancers, potentially improving outcomes, particularly in advanced breast cancer, where treatment options remain limited.
KT-200 demonstrated low-nanomolar CDK2 degradation, strong activity in CCNE1-driven models, potential brain penetration and a favorable safety profile in preclinical studies. It would be Kymera’s first molecular glue candidate to advance into clinical development.
Gilead plans to advance KT-200 into investigational new drug (IND)-enabling studies, with the goal of supporting an IND filing in 2027.
Kymera’s Zacks Rank & Stocks to Consider
KYMR currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 9.68% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 9.95% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.